Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
/PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled...
United States Margaret Wasilewski Timothy Mccarthy Ted Raad Drug Administration Company Quarterly Reports On Form
Source: prnewswire.com